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ABSTRACT
Erosive lichen planus is an uncommon variant of lichen planus. We report a case of longstand-
ing and refractory plantar ELPs causing disabling and opiate-resistant pain treated with ‘classic’
meshed skin graft combined with RigeneraVR micrografts. After approximately 9months follow-
up, no clinical recurrence or pain were observed. Erosive lichen planus (ELP) is an uncommon
variant of lichen planus, involving oral cavity and genitalia and, less often plantar areas, where it
usually presents with chronic erosions of the soles, along with intense, disabling pain and pro-
gressive loss of toenails. An abnormal immune cellular response (CD8þ lymphocytes and macro-
phages) and the consequent altered production of multiple mediators (interleukin-12,
interferon-c, tumor necrosis factor-a, RANTES and MMP-9), seem to play a crucial role in the
pathogenesis, although the etiology remains uncertain. From a histological point of view, ELP
shows keratinocyte apoptosis, intense inflammatory response and basal epithelial keratinocytes
TNF-a overexpression. Several therapies have been proposed, with variable and controversial
results. While topical corticosteroids and topical calcineurin inhibitors are the treatments of
choice for localized forms, short pulses of systemic glucocorticoids, phototherapy, and systemic
immunosuppressants are recommended for generalized cases. Surgery has been reported as a
possible therapeutic option in refractory and stable cases with localized lesions, either alone or
with cyclosporine. Herein, we report a case of longstanding and refractory plantar ELPS causing
disabling and opiate-resistant pain treated with ‘classic’ meshed skin graft combined with
RigeneraVR micrografts.
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A 65-year-old Caucasian female presented with a 6-
year history of a wide and extremely painful ulceration
on the sole of her left foot, histologically diagnosed as
erosive lichen planus. Over the years she had under-
gone several topical and systemic treatments, includ-
ing steroids, antibiotics, retinoid and mycophenolate
mophetil, with transient and incomplete results.Skin
examination revealed an extensive, malodorous and
irregular ulcer, having well-defined margins and a red-
dish and friable base (Figure 1).
Patient reported strong pain and a burning sensa-
tion which impeded her to walk. Absence of toenails
was also evident. Medical history included many
comorbidities, viz. type-2 diabetes, hypertension, disli-
pidemia, obesity, chronic renal failure, IgG k gammop-
athy, multifactorial anemia, erosive gastritis, and
esophagitis. Laboratory tests showed only some altera-
tions related to the patient’s comorbidity and an
increase in the Erythrocyte Sedimentation Rate
(38mm/h) and the C-reactive protein level (1.56mg/L).
Anti-hepatitis C and B viruses’ antibodies
were negative.
Steroid topical preparations were applied under
occlusive wet dressings and systemic Methotrexate
was started with a dosage of 15mg once a week. The
ulcer showed a moderate improvement with increase
of granulation tissue at the base but without effect on
the pain (steadily with NRS scale score >7), which
turned out to be intense and resistant to any type of
analgesic, including opiates, with consequent compro-
mising of her life quality. For this reason, we proposed
her a surgical treatment, consisting in the combination
of a meshed split thickness autologous skin graft, and
autologous skin micro-grafts (obtained by RigeneraVR ).
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Surgery was performed under local anesthesia with
sedation. After surgical debridement of the plantar
lesion, two 3mm2 skin punch biopsies where taken
from the left thigh and processed through RigeneraVR
at 80 rpm for 2min in 3ml of 0.9% NaCl saline solu-
tion, each. The resulting solution was injected on mar-
gins and bottom of the lesion (Figure 2). Then, the
area was covered with a 1:2 meshed split thickness
skin graft taken from her left thigh, and a nonadher-
ent gauze and sterile gauze compression dressing.
After 5 days, the compression dressing was
removed, showing a gook skin engraftment, and com-
plete re-epithelialization after 14 days (Figures 3
and 4).
The patient referred immediate, complete and sta-
ble regression of pain and local symptoms.
After hospital discharge, weekly medications in out-
patient service followed, with progressive improve-
ment of the skin engraftment and no reappearance of
pain. Methotrexate was continued with a reduced
dose of 10mg once a week. The patient has been fol-
lowed-up for approximately 9months and neither clin-
ical recurrence nor pain occurred.
Discussion
The repair and regeneration of human tissues is par-
ticularly difficult and given that regenerative ability
declines with increasing age. The dramatic rise in the
ageing population worldwide determined an
increasing need for innovative approaches. Many
approaches can be used when the normal process of
tissue regeneration is impaired or simply insufficient,
such as grafting which includes autografts, allografts,
xenografts, and biomaterial substitutes [1,2].
Treatment of ELP is notoriously difficult, because of
its frequent resistance to topical or systemic therapies
and high rates of recurrence. Multiple treatment
options have been proposed, but none of them has
consistently demonstrated satisfactory remission of
symptoms. Surgery could be an important alternative
treatment for this disease [3].
In a previous case of ELP, the patient demonstrated
a notable clinical response using cyclosporine and skin
grafting [4]. In the present patient, the numerous
comorbidities prevented the use of different immuno-
suppressants. As prescribed by Dermatologists, metho-
trexate was here used, albeit in the literature there
Figure 1. Extensive, malodorous and irregular ulcer, having
well-defined margins and a reddish and friable base.
Figure 2. Injection of solution containing autologous micro-
grafts obtained with RigeneraVR protocol.
Figure 3. Skin engraftment after 5 days.
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was no previous data on its use in plantar ELP.
Notably, even though we did not observe complete
disease resolution, we obtained partial reduction of
inflammation and increase of granulation tissue, that
might have favored the surgical approach.
At the same time, it is known that immunosuppres-
sive therapy causes an increased risk of delayed
wound healing, infections and failure of the skin grafts
engraftment [5,6]. Referring to all these variables, we
had to consider an alternative solution, which would
accelerate reepithelization, such as using micro-grafts.
In our experience we have already tested their validity
in other wound types [7].
We choose autologous skin micro-grafts obtained
by RigeneraVR technology using a class I medical device
called Rigeneracons (Human Brain Wave, Italy), already
used in various fields of medicine and dentistry [8–10].
We applied the same RigeneraVR protocol reported
in the literature [8–13].
Micrograft technique in this patient had
five functions:
1. Acceleration of skin wound healing: studies have
shown a more rapid reepithelization when micro-
grafts are associated with classic skin graft, with a
better result also in terms of skin quality [11,12].
In vitro results show that the micrografts obtained
with RigeneraVR maintain a high cell viability, des-
pite the disaggregation needed to obtain them. In
particular, micrografts were described rich in mes-
enchymal stem cells (MSCs), with high CD90,
CD73, and CD105 positivity [13,14]. Preclinical and
clinical trials show that MSC therapy accelerates
wound closure suggesting that it can be promis-
ing for treating wounds with delayed healing
[15,16]. In addition, MSCs promote different stages
of the wound repair process through modulation
of inflammation, promotion of angiogenesis, and
stimulation of cell movement during epithelial
remodeling [17]. On the basis of these evidences,
we can suppose that the regenerative properties
of micrografts can be in part determined by MSCs
activity. This supports the capacity of these micro-
grafts to improve wound healing [18,19], and hav-
ing a more fast and complete reepithelialization
respect to the other advanced dressings, with
excellent results in terms of clinical efficacy and
demonstration of the regenerative capacity of this
method [7].
2. Regenerative effect: in micrografts, the keratino-
cytes and fibroblasts are surrounded by a support-
ive microenvironment, increasing the regenerative
capacity of the cells when transplanted [12]. The
goal of regeneration is implanting so small cells
to ensure an optimal grafting, versus the critical
points of a conventional autologous grafts: their
limited regenerative capacity and the percentage
of cellular death in the receiving site [20]. Cell
characterization by flow cytometry analysis shows
a heterogeneous pool of cells [18,19]. The specific
cell population of these micrografts includes pro-
genitor cells [19], which in association with the
fragment of the Extracellular Matrix (ECM) and
growth factors derived by starting tissue, initiate
biological processes of cell proliferation and differ-
entiation enhancing the wound healing pro-
cess [7,11].
3. Anti-inflammatory effect: this micrograft technique
allows to select factors such as TGF-b1 (which acts
both as a promoter of tissue repair and as a sup-
pressor of excessive inflammation) [18,21,22,23,24]
and alpha-smooth muscle actin (a-SMA), which
plays a central role in the healing process (wound
contraction) and which is produced from myofi-
broblasts, once they have differentiated from
fibroblasts upon stimulation of TGF-b1 present in
the ECM [11].
4. Foot sole sensitivity: TGF-b1 appears to stimulate
the de-differentiation of glial cells to neural crest
stem cells. These cells, in turn, appear to be
involved in the progression of healing and the
restoration of peripheral sensitivity [22].
5. Pain reduction: our patient developed immediate
and permanent pain reduction (NRS 2 at first con-
trol at 5 days, 0 at 14 days, Figure 5). Although in
Figure 4. Skin engraftment after 14 days.
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literature the reduction of pain after treatment
with micrograft has already been reported [6], this
result is to be ascribed to the aforementioned
mediators obtained with this method [11,12]
The impressive clinical outcomes combined with
the laboratory tests, demonstrate that this technology
is really able to stimulate skin regeneration. On the
basis of this evidence, RigeneraVR can offer an efficient
and promising strategy to improve symptoms and
wound healing in patients who exhibit painful and
nonhealing wounds.
Conclusion
In this case report, we presented an alternative use of
autologous micro-grafts obtained with the RigeneraVR
protocol, i.e. treatment of chronic inflammatory condi-
tion as ELP. We believe that the addition of autolo-
gous micrografts to the meshed split thickness skin
grafts not only promoted the skin engraftment and
the healing of the erosive lesions, but also helped to
reverse almost instantly the pain, thanks to the
immunosuppressive and anti-inflammatory properties.
Finally, as showed in our instance, methotrexate
could have a role in preparing the lesions to the surgi-
cal procedure and in ensuring prolonged post-surgery
remission. Yet, future studies are needed to confirm
such a speculation as we did not have data in the
post-suspension period because we did not withdraw
the medication to see the disease evolution due to
ethical reason.
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